Selecta Receives US Grant to Develop Nicotine Vaccine

      Selecta Biosciences has been awarded a $3m grant from the US National Institute on Drug Abuse to advance the development of an enhanced therapeutic nicotine vaccine.

      The vaccine, based on Selecta's tSVP technology, offers a new approach to a nicotine vaccine by boosting immune responses.

     The award is one of a select number of grants provided nationwide by the National Institutes of Health under the Biomedical Research, Development and Growth to Spur the Acceleration of New Technologies Pilot Programme.